Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 350 of 2529 entries
View as:

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Phase: N/A Priority: Normal
NCT ID: NCT04139317 Org: User:
Start: 01/22/20 End: 02/07/23 Due: 02/07/24

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT03152552 Org: User:
Start: 07/25/17 End: 06/06/18 Due: 06/06/19

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Phase: N/A Priority: Normal
NCT ID: NCT04899349 Org: User:
Start: 04/06/22 End: 05/10/23 Due: 05/10/24

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

Phase: N/A Priority: Normal
NCT ID: NCT04980833 Org: User:
Start: 01/27/22 End: 09/01/27 Due: 09/01/28

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Phase: N/A Priority: Normal
NCT ID: NCT00493766 Org: User:
Start: 05/31/06 End: - Due: -

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02077933 Org: User:
Start: 05/14/14 End: 04/12/19 Due: 04/12/20

ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling

Phase: N/A Priority: Normal
NCT ID: NCT01176032 Org: User:
Start: 06/30/10 End: 04/30/13 Due: 04/30/14

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00790426 Org: User:
Start: 03/31/10 End: 04/30/12 Due: 04/30/13

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01698918 Org: User:
Start: 03/07/13 End: 01/13/21 Due: 01/13/22

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00035100 Org: User:
Start: 09/30/01 End: - Due: -

Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients

Phase: N/A Priority: Normal
NCT ID: NCT00154297 Org: User:
Start: 06/30/05 End: - Due: -

Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316

Phase: N/A Priority: Normal
NCT ID: NCT02878616 Org: User:
Start: 08/26/16 End: 07/19/17 Due: 07/19/18

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02087059 Org: User:
Start: 04/30/14 End: 04/30/15 Due: 04/30/16

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

Phase: N/A Priority: Normal
NCT ID: NCT02008916 Org: User:
Start: 01/14/14 End: 12/11/17 Due: 12/11/18

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

Phase: N/A Priority: Normal
NCT ID: NCT00688753 Org: User:
Start: 07/31/09 End: 10/31/14 Due: 10/31/15

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Phase: N/A Priority: Normal
NCT ID: NCT01487460 Org: User:
Start: 11/30/11 End: 06/30/12 Due: 06/30/13

Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients

Phase: N/A Priority: Normal
NCT ID: NCT00457119 Org: User:
Start: 02/28/07 End: 11/30/09 Due: 11/30/10

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00332852 Org: User:
Start: 03/31/06 End: - Due: -

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01584648 Org: User:
Start: 05/04/12 End: 02/28/19 Due: 02/28/20

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT02091752 Org: User:
Start: 09/30/14 End: 02/28/15 Due: 02/28/16

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

Phase: N/A Priority: Normal
NCT ID: NCT03096834 Org: User:
Start: 03/20/17 End: 01/28/21 Due: 01/28/22

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Phase: N/A Priority: Normal
NCT ID: NCT03066804 Org: User:
Start: 08/22/17 End: 10/28/19 Due: 10/28/20

A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India

Phase: N/A Priority: Normal
NCT ID: NCT05834075 Org: User:
Start: 01/05/22 End: 04/22/22 Due: 04/22/23

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Phase: N/A Priority: Normal
NCT ID: NCT01544595 Org: User:
Start: 06/19/12 End: 06/26/17 Due: 06/26/18

Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid

Phase: N/A Priority: Normal
NCT ID: NCT00745485 Org: User:
Start: 08/31/08 End: - Due: -